Combinations of gastrointestinal permeation enhancers for use in compositions and methods to enhance the systemic bioavailability of therapeutic polypeptides undergoing oral administration
Combining gastrointestinal permeation enhancers with therapeutic polypeptides addresses the low oral bioavailability issue by synergistically enhancing gastrointestinal uptake, achieving up to 20 times greater absorption and enabling convenient oral administration.
WO2026125637A1PCT designated stage Publication Date: 2026-06-18ALGIFARMA IPR AS
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ALGIFARMA IPR AS
- Filing Date
- 2025-12-11
- Publication Date
- 2026-06-18
Smart Images
Figure EP2025086688_18062026_PF_FP_ABST
Abstract
The invention provides a method for increasing the systemic bioavailability of a polypeptide therapeutic agent undergoing oral, orogastric, nasogastric, or intragastric administration, said method comprising administering said polypeptide therapeutic agent together with (i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) and (ii) a compound of Formula (II), or a pharmaceutically acceptable salt thereof, (II) to a human or non-human animal subject by oral, orogastric, nasogastric, or intragastric administration. Such methods allow for systemic treatment or prevention of a disease or condition or complication thereof which is responsive to, or which is prevented by, a polypeptide therapeutic agent via oral, orogastric, nasogastric, or intragastric administration routes. Further provided are compositions for use in such methods.
Need to check novelty before this filing date? Find Prior Art